Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

NCT01204307 ↗

Phase 2 Completed 101 enrolled Chang Gung Memorial Hospital Taiwan Chest Disease Association · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the differential influence of 1st line doublet chemotherapy containing Docetaxel versus Pemetrexed on clinical efficacy of Erlotinib as a second line therapy in patients with relapsed or progressed non-squamous NSCLC.

Timeline

Start: 2010-01
Primary completion: 2014-12
Completion: 2015-06

Publications

Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, Lin TY, Chung FT, Kuo CS, Yu CT, Lin SM, Wang CH, Chou CL, Huang CD, Kuo HP. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med. 2012 Nov 15;186(10):1025-36. doi: 10.1164/rccm.201204-0636OC. Epub 2012 Sep 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	30 mg/m2	—
Comparator	Pemetrexed	Small molecule	500 mg/m2	Intravenous
Background	Cisplatin	Other / unclassified	37.5 mg/m2	—
Background	Cisplatin	Other / unclassified	75 mg/m2	—

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Summary

Timeline

Publications

Drugs

Indications